Published on 1 Feb 2023 on Zacks via Yahoo Finance
Edwards Lifesciences Corporation EW delivered fourth-quarter 2022 adjusted earnings per share (EPS) of 64 cents, beating the Zacks Consensus Estimate by 4.9%. The figure also increased 25.5% year over year.
Full-year adjusted EPS was $2.48, up 11.7% from the year-ago number. The metric surpassed the Zacks Consensus Estimate by 1.2%.
Our model projected an adjusted EPS of 58 cents for Q4 and $2.42 per share for 2022.